共 24 条
- [9] Systematic Review of Interleukin-12, Interleukin-17, and Interleukin-23 Pathway Inhibitors for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis: Ustekinumab, Briakinumab, Tildrakizumab, Guselkumab, Secukinumab, Ixekizumab, and Brodalumab JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2014, 18 (03) : 156 - 169
- [10] Effects of tumor necrosis factor-, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis JOURNAL OF DERMATOLOGY, 2018, 45 (09): : 1130 - 1134